Kymera prices $225M offering of common stock and pre-funded warrants

Kymera Therapeutics, Inc.

Selling 2,002,313 shares at $40.75 and 3,519,159 pre-funded warrants at $40.7499.
Net proceeds estimated at ~$246.5M after underwriting discounts and expenses.
Underwriters exercised 30-day option to purchase additional 828,220 shares in full.
Proceeds to advance preclinical and clinical degrader programs and for working capital.
Existing cash plus offering proceeds expected to fund operations into mid 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.